Shanghai Rightongene Biotechnology Future Growth
Future criteria checks 4/6
Shanghai Rightongene Biotechnology is forecast to grow earnings and revenue by 26.7% and 19.3% per annum respectively. EPS is expected to grow by 27% per annum. Return on equity is forecast to be 1.5% in 3 years.
Key information
26.7%
Earnings growth rate
27.0%
EPS growth rate
Biotechs earnings growth | 33.2% |
Revenue growth rate | 19.3% |
Future return on equity | 1.5% |
Analyst coverage | Low |
Last updated | 22 Apr 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 453 | 17 | N/A | 63 | 1 |
12/31/2025 | 375 | 14 | N/A | 41 | 1 |
12/31/2024 | 311 | 12 | N/A | 65 | 1 |
3/31/2024 | 266 | 7 | -56 | 20 | N/A |
12/31/2023 | 258 | 8 | -64 | 45 | N/A |
9/30/2023 | 351 | 23 | -43 | 101 | N/A |
6/30/2023 | 379 | 35 | -38 | 96 | N/A |
3/31/2023 | 433 | 44 | 5 | 107 | N/A |
12/31/2022 | 424 | 40 | -33 | 73 | N/A |
9/30/2022 | 354 | 41 | -40 | 34 | N/A |
6/30/2022 | 328 | 44 | -47 | 45 | N/A |
3/31/2022 | 274 | 29 | -47 | 61 | N/A |
12/31/2021 | 291 | 47 | -18 | 78 | N/A |
9/30/2021 | 289 | 53 | -17 | 66 | N/A |
6/30/2021 | 285 | 50 | 1 | 83 | N/A |
3/31/2021 | 307 | 53 | 16 | 84 | N/A |
12/31/2020 | 285 | 39 | 18 | 70 | N/A |
12/31/2019 | 255 | 36 | -42 | 12 | N/A |
12/31/2018 | 224 | 15 | -45 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688217's forecast earnings growth (26.7% per year) is above the savings rate (2.9%).
Earnings vs Market: 688217's earnings (26.7% per year) are forecast to grow faster than the CN market (23.4% per year).
High Growth Earnings: 688217's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688217's revenue (19.3% per year) is forecast to grow faster than the CN market (14.1% per year).
High Growth Revenue: 688217's revenue (19.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688217's Return on Equity is forecast to be low in 3 years time (1.5%).